Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?
Tolvaptan is a highly selective vasopressin receptor 2 antagonist that regulates cyclic adenosine monophosphate levels to inhibit both epithelial cell proliferation Light Weight and chloride ion excretion, two mechanisms known to induce cyst expansion in autosomal dominant polycystic kidney disease (ADPKD).Tolvaptan is currently the preferred treat